Literature DB >> 10433240

Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells.

S W Mitra1, E Mezey, B Hunyady, L Chamberlain, E Hayes, F Foor, Y Wang, A Schonbrunn, J M Schaeffer.   

Abstract

Somatostatin, also known as somatotropin release-inhibiting factor (SRIF), is secreted by pancreatic delta-cells and inhibits the secretion of both insulin and glucagon. SRIF initiates its actions by binding to a family of six G protein-coupled receptors (sst1, -2A, -2B, -3, -4, and -5) encoded by five genes. Messenger RNA for both sst2 and sst5 have been reported in the rat pancreas, and the sst2A receptor protein has been localized to rat pancreatic alpha and pancreatic polypeptide-secreting cells in the islets as well as to pancreatic acinar cells. In this study we have used double immunostaining to show that the sst5 protein is expressed exclusively in the beta-cells of rat pancreatic islets and localizes with insulin-secreting alpha-cells. The sst5 receptor is not colocalized with sst2A. Thus, in the rat SRIF inhibits pancreatic insulin and glucagon secretion via different sst receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433240     DOI: 10.1210/endo.140.8.6937

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  16 in total

Review 1.  Autonomic dysfunction of the beta-cell and the pathogenesis of obesity.

Authors:  Robert H Lustig
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 2.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

3.  Theoretical analysis of somatostatin receptor 5 with antagonists and agonists for the treatment of neuroendocrine tumors.

Authors:  Santhosh Kumar Nagarajan; Sathya Babu; Thirumurthy Madhavan
Journal:  Mol Divers       Date:  2017-02-02       Impact factor: 2.943

4.  Sulfonylurea receptor knockout causes glucose intolerance in mice that is not alleviated by concomitant somatostatin subtype receptor 5 knockout.

Authors:  Michael Norman; Stefan Moldovan; Victor Seghers; Xiao-Ping Wang; Francesco J DeMayo; F Charles Brunicardi
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

Review 5.  Somatostatin receptors and their interest in diagnostic pathology.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Mauro Papotti
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

6.  Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children.

Authors:  Robert H Lustig; Michele L Mietus-Snyder; Peter Bacchetti; Ann A Lazar; Pedro A Velasquez-Mieyer; Michael L Christensen
Journal:  J Pediatr       Date:  2006-01       Impact factor: 4.406

7.  Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults.

Authors:  P A Velasquez-Mieyer; P A Cowan; K L Arheart; C K Buffington; K A Spencer; B E Connelly; G W Cowan; R H Lustig
Journal:  Int J Obes Relat Metab Disord       Date:  2003-02

8.  Effects of two different somatostatin analogs on glucose tolerance in acromegaly.

Authors:  C Ronchi; P Epaminonda; V Cappiello; P Beck-Peccoz; M Arosio
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

9.  Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release.

Authors:  Seongjoon Park; Hong Jiang; Hongjie Zhang; Roy G Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-29       Impact factor: 11.205

10.  Adrenaline but not noradrenaline is a determinant of exercise-induced lipid mobilization in human subcutaneous adipose tissue.

Authors:  I de Glisezinski; D Larrouy; M Bajzova; K Koppo; J Polak; M Berlan; J Bulow; D Langin; M A Marques; F Crampes; M Lafontan; V Stich
Journal:  J Physiol       Date:  2009-05-05       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.